Rights to botulinum toxin type b Neurobloc® in Europe transferred to Sloan Pharma, s.à.r.l.
- Category: Proteins and Peptides
- Published on Friday, 30 March 2018 09:38
- Hits: 1297
TOKYO, Japan I March 30, 2018 I Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito; “Eisai”) announced today that it has entered into an agreement with Sloan Pharma, S.à.r.l., Switzerland (“Sloan Pharma”), a wholly-owned subsidiary of US WorldMeds, LLC (Headquarters: Louisville, Kentucky, USA, CEO: Paul Breckinridge Jones), to transfer to Sloan Pharma exclusive development and marketing rights for botulinum toxin type B Neurobloc® (“the agent”) in Europe. Under this agreement, Eisai will receive a one-time payment from Sloan Pharma.
In May 2007, Eisai entered into an agreement with Solstice Neurosciences, LLC for the rights to further develop and commercialize the agent in Europe, and Eisai has been marketing the agent which was approved as a treatment for cervical dystonia in Europe. In 2010, Solstice Neurosciences, LLC was acquired by and reorganized as a wholly-owned subsidiary of US WorldMeds, LLC, which currently markets the agent under the product name MYOBLOC (rimabotulinumtoxinB) Injection in the United States. Transferring the rights for the agent in Europe to Sloan Pharma, which, as part of the US WorldMeds group, has strengths in neurology as well as knowledge of the commercialization and development of pharmaceutical products, will enable greater contributions to cervical dystonia patients in Europe
In Japan, Eisai has conducted development of the agent and obtained approval for the treatment of cervical dystonia. Eisai has been marketing the agent in Japan under the product name NerBloc® since March 2013 and will continue to do so in the future
Eisai positions neurology and oncology as key therapeutic areas. By accelerating the development of its innovative new drugs in these areas and pursuing optimal business models to match regional characteristics, Eisai seeks to contribute further to addressing the diverse patient needs of, and increasing the benefits for, patients and their families worldwide.
1. About US WorldMeds, LLC
US WorldMeds, LLC is a specialty pharmaceutical company whose treatment options are making a difference in the lives of the patients and communities it serves.
Headquartered in Louisville, Kentucky, US WorldMeds has global presence and more than 15 years of experience in the development, licensure, and commercialization of unique pharmaceutical products designed to improve the lives of patients with challenging conditions and unmet medical needs.
The company is inspired by the patients and communities it serves and strives to offer treatment options that can make a difference in their lives. US WorldMeds takes an entrepreneurial, agile, and personal approach to pharmaceuticals – pioneering research and product development in therapeutic areas that are in need of new solutions.
For more information about US WorldMeds, visit http://www.usworldmeds.com/